https://www.selleckchem.com/pr....oducts/bpv-hopic.htm
0 [0;3], p = .001). When adjusting for baseline differences, MT remained a determinant of MVO occurrence and extent (odds ratio, OR 1.802 [95% confidence interval, CI 1.080-3.009], p = .024) and β = .137, p = .024) in patients with a high thrombus grade. CONCLUSION In STEMI patients, MT was associated with the occurrence and extent of MVO, on CMR, especially in patients with a high thrombus burden. © 2020 Wiley Periodicals, Inc.This article describes the development and assessment of a Nutritional Genomics course, designed to be held